Unicycive Therapeutics, Inc.
UNCY
Positions held
Your positionsUNCY isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $111.49M | Enterprise value | $52.62M | Trailing P/E | — | Forward P/E | 2.41 |
| PEG | — | Price / book | 2.13 | Beta | 1.82 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -101.1% | ROA | -40.6% | Debt / equity | 0.01 |
| Current ratio | 3.81 | Free cash flow | -$12.72M | Analyst recommendation | strong_buy | Mean target | $28.40 |
| 52w high | $8.74 | 52w low | $3.93 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$1.7M | -$12.8M | -$14.7M | -$6.0M | -$6.4M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$10.1M | -$8.4M | -$7.2M | -$7.3M | -$7.0M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.7M | $1.0M | — |
| Op margin | — | — | -3077.6% | -1898.2% | — |
| Net income | -$26.6M | -$36.7M | -$30.5M | -$18.1M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$29.5M | -$32.1M | -$20.8M | -$18.1M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-01 · Unicycive Therapeutics Appoints Meredith Manning to Board of Directors
2026-09-29 · Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate
2026-09-01 · Unicycive Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-08-13 · B. Riley Adjusts Price Target on Unicycive Therapeutics to $20 From $22, Maintains Buy Rating
2026-08-12 · Unicycive Therapeutics shares rise after second-quarter loss beats forecasts
2026-08-12 · Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
Price (daily)
Full chart · RSI · MACD · patterns